Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira reports preliminary 2025 revenue of $726.4 million, up from $701.0 million

Positive Impact 3 of 5 earnings Written later

Pacira BioSciences reported preliminary, unaudited total revenue of $726.4 million for 2025, compared with $701.0 million in 2024, with fourth-quarter EXPAREL net product sales of $155.8 million. The figures are subject to adjustment, and the company expects to report complete fourth-quarter and full-year 2025 results and financial guidance later in the first quarter of 2026.

Key points

  • Full-year 2025 total revenue of $726.4 million, compared with $701.0 million in 2024.
  • Full-year EXPAREL net product sales of $575.1 million, compared with $549.0 million, with volume growth of 6 percent.
  • During the fourth quarter of 2025, the company repurchased 2.0 million shares for $50.0 million; $150.0 million remains on its authorization, which expires December 31, 2026.

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECJan 8, 2026, 4:02 PM ET
Accession number0001628280-26-001335

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 08, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.